BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amundadottir LT. Pancreatic Cancer Genetics. Int J Biol Sci 2016;12:314-25. [PMID: 26929738 DOI: 10.7150/ijbs.15001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 12.2] [Reference Citation Analysis]
Number Citing Articles
1 Streicher SA, Klein AP, Olson SH, Amundadottir LT, DeWan AT, Zhao H, Risch HA. Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews. Cancer Epidemiol Biomarkers Prev 2017;26:1540-8. [PMID: 28754795 DOI: 10.1158/1055-9965.EPI-17-0262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Yang T, Li J, Wen Y, Tan T, Yang J, Pan J, Hu C, Yao Y, Zhang J, Xin Y, Li S, Xia H, He J, Zou Y. LINC00673 rs11655237 C>T Polymorphism Impacts Hepatoblastoma Susceptibility in Chinese Children. Front Genet 2019;10:506. [PMID: 31178901 DOI: 10.3389/fgene.2019.00506] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
3 Hussain SP. Pancreatic Cancer: Current Progress and Future Challenges. Int J Biol Sci 2016;12:270-2. [PMID: 26929733 DOI: 10.7150/ijbs.14950] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
4 Guo F, Zhou Y, Guo H, Ren D, Jin X, Wu H. NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15. Cell Death Discov 2021;7:78. [PMID: 33850096 DOI: 10.1038/s41420-021-00462-8] [Reference Citation Analysis]
5 Zhang L, Bluth MH, Bhalla A. Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract: 2018 Update. Clin Lab Med 2018;38:367-84. [PMID: 29776636 DOI: 10.1016/j.cll.2018.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Gentiluomo M, Corradi C, Vanella G, Johansen AZ, Strobel O, Szentesi A, Milanetto AC, Hegyi P, Kupcinskas J, Tavano F, Neoptolemos JP, Bozzato D, Hackert T, Pezzilli R, Johansen JS, Costello E, Mohelnikova-Duchonova B, van Eijck CHJ, Talar-Wojnarowska R, Hansen CP, Darvasi E, Chen IM, Cavestro GM, Soucek P, Piredda L, Vodicka P, Gazouli M, Arcidiacono PG, Canzian F, Campa D, Capurso G. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Sci Rep 2021;11:7570. [PMID: 33828170 DOI: 10.1038/s41598-021-87130-0] [Reference Citation Analysis]
7 Slavin TP, Neuhausen SL, Nehoray B, Niell-Swiller M, Solomon I, Rybak C, Blazer K, Adamson A, Yang K, Sand S, Guerrero-Llamas N, Castillo D, Herzog J, Wu X, Tao S, Raja S, Chung V, Singh G, Nadesan S, Brown S, Cruz-Correa M, Petersen GM, Weitzel J; Clinical Cancer Genomics Community Research Network (CCGCRN). The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 2018;17:235-45. [PMID: 28687971 DOI: 10.1007/s10689-017-0019-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
8 Arnes L, Liu Z, Wang J, Maurer C, Sagalovskiy I, Sanchez-Martin M, Bommakanti N, Garofalo DC, Balderes DA, Sussel L, Olive KP, Rabadan R. Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Gut 2019;68:499-511. [PMID: 29440233 DOI: 10.1136/gutjnl-2017-314353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
9 Wiest NE, Moktan VP, Oman SP, Chirilă RM. Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 2020;58:119-28. [PMID: 32364522 DOI: 10.2478/rjim-2020-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shen GQ, Aleassa EM, Walsh RM, Morris-Stiff G. Next-Generation Sequencing in Pancreatic Cancer. Pancreas 2019;48:739-48. [PMID: 31206465 DOI: 10.1097/MPA.0000000000001324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
11 Witte D, Zeeh F, Gädeken T, Gieseler F, Rauch BH, Settmacher U, Kaufmann R, Lehnert H, Ungefroren H. Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-β Signaling in Pancreatic Cancer. J Clin Med 2016;5:E111. [PMID: 27916875 DOI: 10.3390/jcm5120111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
12 Zhao L, Liu H, Luo S, Moorman PG, Walsh KM, Li W, Wei Q. Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk. Cancer Med 2020;9:9620-31. [PMID: 33200553 DOI: 10.1002/cam4.3603] [Reference Citation Analysis]
13 Michl P, Löhr M, Neoptolemos JP, Capurso G, Rebours V, Malats N, Ollivier M, Ricciardiello L. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterol J 2021. [PMID: 34431604 DOI: 10.1002/ueg2.12123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang W, Liu H, Duan B, Xu X, Carmody D, Luo S, Walsh KM, Abbruzzese JL, Zhang X, Chen X, Wei Q. Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk. Cancer Sci 2019;110:2022-32. [PMID: 30972876 DOI: 10.1111/cas.14017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Gromisch C, Qadan M, Machado MA, Liu K, Colson Y, Grinstaff MW. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Res 2020;80:3179-92. [PMID: 32220831 DOI: 10.1158/0008-5472.CAN-19-2731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
16 Silke J, O'Reilly LA. NF-κB and Pancreatic Cancer; Chapter and Verse. Cancers (Basel) 2021;13:4510. [PMID: 34572737 DOI: 10.3390/cancers13184510] [Reference Citation Analysis]
17 Morani AC, Hanafy AK, Ramani NS, Katabathina VS, Yedururi S, Dasyam AK, Prasad SR. Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging. Radiol Imaging Cancer 2020;2:e190020. [PMID: 33778702 DOI: 10.1148/rycan.2020190020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Gentiluomo M, Peduzzi G, Lu Y, Campa D, Canzian F. Genetic polymorphisms in inflammatory genes and pancreatic cancer risk: a two-phase study on more than 14 000 individuals. Mutagenesis 2019. [DOI: 10.1093/mutage/gez040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Abrams SL, Akula SM, Martelli AM, Cocco L, Ratti S, Libra M, Candido S, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS, McCubrey JA. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Adv Biol Regul 2021;79:100780. [PMID: 33451973 DOI: 10.1016/j.jbior.2020.100780] [Reference Citation Analysis]
20 Galeotti AA, Gentiluomo M, Rizzato C, Obazee O, Neoptolemos JP, Pasquali C, Nentwich M, Cavestro GM, Pezzilli R, Greenhalf W, Holleczek B, Schroeder C, Schöttker B, Ivanauskas A, Ginocchi L, Key TJ, Hegyi P, Archibugi L, Darvasi E, Basso D, Sperti C, Bijlsma MF, Palmieri O, Hlavac V, Talar-Wojnarowska R, Mohelnikova-Duchonova B, Hackert T, Vashist Y, Strouhal O, van Laarhoven H, Tavano F, Lovecek M, Dervenis C, Izbéki F, Padoan A, Małecka-Panas E, Maiello E, Vanella G, Capurso G, Izbicki JR, Theodoropoulos GE, Jamroziak K, Katzke V, Kaaks R, Mambrini A, Papanikolaou IS, Szmola R, Szentesi A, Kupcinskas J, Bursi S, Costello E, Boggi U, Milanetto AC, Landi S, Gazouli M, Vodickova L, Soucek P, Gioffreda D, Gemignani F, Brenner H, Strobel O, Büchler M, Vodicka P, Paiella S, Canzian F, Campa D. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J Med Genet 2021;58:369-77. [PMID: 32591343 DOI: 10.1136/jmedgenet-2020-106961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
21 Rudno-Rudzińska J, Kielan W, Guziński M, Płochocki M, Antończyk A, Kulbacka J. New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP) - A pilot preclinical study. Surg Oncol 2021;38:101634. [PMID: 34303953 DOI: 10.1016/j.suronc.2021.101634] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. Onco Targets Ther 2020;13:12705-20. [PMID: 33335406 DOI: 10.2147/OTT.S220971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Xu M, He J, Li J, Feng W, Zhou H, Wei H, Zhou M, Lu Y, Zeng J, Peng W, Du F, Gong A. Methyl-CpG-binding domain 3 inhibits epithelial-mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling. Br J Cancer 2017;116:91-9. [PMID: 27898661 DOI: 10.1038/bjc.2016.397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
24 Cobo I, Iglesias M, Flández M, Verbeke C, Del Pozo N, Llorente M, Lawlor R, Luchini C, Rusev B, Scarpa A, Real FX. Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions. J Pathol 2021;253:174-85. [PMID: 33079429 DOI: 10.1002/path.5570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava M, Michalski CW, Farré A, Molero X, Löhr M, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Balsells J, Costello E, Yu J, Iglesias M, Ilzarbe L, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Lawlor RT, Ye W, Hidalgo M, Scarpa A, Sharp L, Carrato A, Real FX, Furlong LI, Malats N; PanGenEU Study Investigators. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Int J Cancer 2019;144:1540-9. [PMID: 30229903 DOI: 10.1002/ijc.31866] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Principe DR, Rana A. Updated risk factors to inform early pancreatic cancer screening and identify high risk patients. Cancer Lett 2020;485:56-65. [PMID: 32389710 DOI: 10.1016/j.canlet.2020.04.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Chang J, Tian J, Zhu Y, Zhong R, Zhai K, Li J, Ke J, Han Q, Lou J, Chen W, Zhu B, Shen N, Zhang Y, Gong Y, Yang Y, Zou D, Peng X, Zhang Z, Zhang X, Huang K, Yang M, Wang L, Wu C, Lin D, Miao X. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Nat Commun 2018;9:3688. [PMID: 30206226 DOI: 10.1038/s41467-018-06136-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
28 Zhao L, Li C, Liu F, Zhao Y, Liu J, Hua Y, Liu J, Huang J, Ge C. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther 2017;10:2115-26. [PMID: 28442920 DOI: 10.2147/OTT.S130481] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
29 Scarpa A, Mafficini A. Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. Gut 2018;67:399-400. [PMID: 28659348 DOI: 10.1136/gutjnl-2017-314310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
30 Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A, Perea J, Greenhalf W, Ilzarbe L, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Balsells J, Costello E, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Scarpa A, Ye W, Hidalgo M, Sharp L, Carrato A, Real FX, Malats N; PanGenEU Study Investigators. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Int J Epidemiol 2018;47:473-83. [PMID: 29329392 DOI: 10.1093/ije/dyx269] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
31 Lu Y, Gentiluomo M, Lorenzo-Bermejo J, Morelli L, Obazee O, Campa D, Canzian F. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. J Med Genet 2020;57:820-8. [PMID: 32066631 DOI: 10.1136/jmedgenet-2019-106200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
32 Cobo I, Martinelli P, Flández M, Bakiri L, Zhang M, Carrillo-de-Santa-Pau E, Jia J, Sánchez-Arévalo Lobo VJ, Megías D, Felipe I, Del Pozo N, Millán I, Thommesen L, Bruland T, Olson SH, Smith J, Schoonjans K, Bamlet WR, Petersen GM, Malats N, Amundadottir LT, Wagner EF, Real FX. Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. Nature 2018;554:533-7. [PMID: 29443959 DOI: 10.1038/nature25751] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 19.3] [Reference Citation Analysis]
33 Li R, Zhang J, Ma S, Zhao G, Li J, Li J, Wang X, Hui B. lncRNA IUR upregulates miR-34a to inhibit pancreatic adenocarcinoma cell migratory and invasive abilities. Oncol Lett 2021;22:567. [PMID: 34113395 DOI: 10.3892/ol.2021.12828] [Reference Citation Analysis]
34 Boldes T, Merenbakh-Lamin K, Journo S, Shachar E, Lipson D, Yeheskel A, Pasmanik-Chor M, Rubinek T, Wolf I. R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers. BMC Cancer 2020;20:531. [PMID: 32513126 DOI: 10.1186/s12885-020-07005-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Campa D, Gentiluomo M, Obazee O, Ballerini A, Vodickova L, Hegyi P, Soucek P, Brenner H, Milanetto AC, Landi S, Gao X, Bozzato D, Capurso G, Tavano F, Vashist Y, Hackert T, Bambi F, Bursi S, Oliverius M, Gioffreda D, Schöttker B, Ivanauskas A, Mohelnikova-Duchonova B, Darvasi E, Pezzilli R, Małecka-Panas E, Strobel O, Gazouli M, Katzke V, Szentesi A, Cavestro GM, Farkas G Jr, Izbicki JR, Moz S, Archibugi L, Hlavac V, Vincze Á, Talar-Wojnarowska R, Rusev B, Kupcinskas J, Greenhalf B, Dijk F, Giese N, Boggi U, Andriulli A, Busch OR, Vanella G, Vodicka P, Nentwich M, Lawlor RT, Theodoropoulos GE, Jamroziak K, Zuppardo RA, Moletta L, Ginocchi L, Kaaks R, Neoptolemos JP, Lucchesi M, Canzian F. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Int J Cancer 2020;147:2065-74. [PMID: 32270874 DOI: 10.1002/ijc.33004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
36 Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A. Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program. Hered Cancer Clin Pract 2019;17:30. [PMID: 31666883 DOI: 10.1186/s13053-019-0129-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Katabathina VS, Rikhtehgar OY, Dasyam AK, Manickam R, Prasad SR. Genetics of Pancreatic Neoplasms and Role of Screening. Magn Reson Imaging Clin N Am. 2018;26:375-389. [PMID: 30376976 DOI: 10.1016/j.mric.2018.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Aoki MN, Stein A, de Oliveira JC, Chammas R, Uno M, Munhoz FBA, Marin AM, Canzian F. Susceptibility loci for pancreatic cancer in the Brazilian population. BMC Med Genomics 2021;14:111. [PMID: 33879152 DOI: 10.1186/s12920-021-00956-5] [Reference Citation Analysis]
39 Bhat IA, Kabeer SW, Reza MI, Mir RH, Dar MO. AdipoRon: A Novel Insulin Sensitizer in Various Complications and the Underlying Mechanisms: A Review. Curr Mol Pharmacol 2020;13:94-107. [PMID: 31642417 DOI: 10.2174/1874467212666191022102800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Cuomo D, Porreca I, Cobellis G, Tarallo R, Nassa G, Falco G, Nardone A, Rizzo F, Mallardo M, Ambrosino C. Carcinogenic risk and Bisphenol A exposure: A focus on molecular aspects in endoderm derived glands. Molecular and Cellular Endocrinology 2017;457:20-34. [DOI: 10.1016/j.mce.2017.01.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
41 Ashktorab H, Kupfer SS, Brim H, Carethers JM. Racial Disparity in Gastrointestinal Cancer Risk. Gastroenterology. 2017;153:910-923. [PMID: 28807841 DOI: 10.1053/j.gastro.2017.08.018] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 24.8] [Reference Citation Analysis]
42 O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5:1431-1438. [PMID: 31318392 DOI: 10.1001/jamaoncol.2019.1588] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 55.0] [Reference Citation Analysis]
43 Lombardo D, Silvy F, Crenon I, Martinez E, Collignon A, Beraud E, Mas E. Pancreatic adenocarcinoma, chronic pancreatitis, and MODY-8 diabetes: is bile salt-dependent lipase (or carboxyl ester lipase) at the crossroads of pancreatic pathologies? Oncotarget 2018;9:12513-33. [PMID: 29552330 DOI: 10.18632/oncotarget.23619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Bracci PM. Oral Health and the Oral Microbiome in Pancreatic Cancer: An Overview of Epidemiological Studies. Cancer J. 2017;23:310-314. [PMID: 29189325 DOI: 10.1097/ppo.0000000000000287] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
45 Obazee O, Archibugi L, Andriulli A, Soucek P, Małecka-panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, Cavestro GM, Milanetto AC, Di Leo M, Pasquali C, Hegyi P, Szentesi A, Radu CE, Gheorghe C, Theodoropoulos GE, Bergmann F, Brenner H, Vodickova L, Katzke V, Campa D, Strobel O, Kaiser J, Pezzilli R, Federici F, Mohelnikova-duchonova B, Boggi U, Lemstrova R, Johansen JS, Bojesen SE, Chen I, Jensen BV, Capurso G, Pazienza V, Dervenis C, Sperti C, Mambrini A, Hackert T, Kaaks R, Basso D, Talar-wojnarowska R, Maiello E, Izbicki JR, Cuk K, Saum KU, Cantore M, Kupcinskas J, Palmieri O, Delle Fave G, Landi S, Salvia R, Fogar P, Vashist YK, Scarpa A, Vodicka P, Tjaden C, Iskierka-jazdzewska E, Canzian F. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma: Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Int J Cancer 2019;145:686-93. [DOI: 10.1002/ijc.32127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
46 Karmakar S, Kaushik G, Nimmakayala R, Rachagani S, Ponnusamy MP, Batra SK. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. Semin Cancer Biol 2019;54:63-71. [PMID: 29199014 DOI: 10.1016/j.semcancer.2017.11.020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
47 Ungefroren H, Witte D, Rauch BH, Settmacher U, Lehnert H, Gieseler F, Kaufmann R. Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling. Int J Mol Sci 2017;18:E2494. [PMID: 29165389 DOI: 10.3390/ijms18112494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
48 Skaro M, Nanda N, Gauthier C, Felsenstein M, Jiang Z, Qiu M, Shindo K, Yu J, Hutchings D, Javed AA, Beckman R, He J, Wolfgang CL, Thompson E, Hruban RH, Klein AP, Goggins M, Wood LD, Roberts NJ. Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology 2019;156:1905-13. [PMID: 30716324 DOI: 10.1053/j.gastro.2019.01.254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
49 Moschovis D, Vasilaki E, Tzouvala M, Karamanolis G, Katifelis H, Legaki E, Vezakis A, Aravantinos G, Gazouli M. Association between genetic polymorphisms in long non-coding RNAs and pancreatic cancer risk. Cancer Biomark. 2019;24:117-123. [PMID: 30475759 DOI: 10.3233/cbm-181959] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
50 Gentiluomo M, Lu Y, Canzian F, Campa D. Genetic variants in taste-related genes and risk of pancreatic cancer. Mutagenesis 2019;34:391-4. [PMID: 31606007 DOI: 10.1093/mutage/gez032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
51 Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anticancer Drugs 2017;28:127-32. [PMID: 27685167 DOI: 10.1097/CAD.0000000000000437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Todoric J, Karin M. The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer. Cancer Cell 2019;35:714-20. [PMID: 31085174 DOI: 10.1016/j.ccell.2019.04.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
53 Zhong J, Jermusyk A, Wu L, Hoskins JW, Collins I, Mocci E, Zhang M, Song L, Chung CC, Zhang T, Xiao W, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt S, Borgida A, Bracci PM, Brais L, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Childs EJ, Cotterchio M, Du M, Duell EJ, Fuchs C, Gallinger S, Gaziano JM, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Haiman C, Hartge P, Hasan M, Helzlsouer KJ, Holly EA, Klein EA, Kogevinas M, Kurtz RJ, LeMarchand L, Malats N, Männistö S, Milne R, Neale RE, Ng K, Obazee O, Oberg AL, Orlow I, Patel AV, Peters U, Porta M, Rothman N, Scelo G, Sesso HD, Severi G, Sieri S, Silverman D, Sund M, Tjønneland A, Thornquist MD, Tobias GS, Trichopoulou A, Van Den Eeden SK, Visvanathan K, Wactawski-Wende J, Wentzensen N, White E, Yu H, Yuan C, Zeleniuch-Jacquotte A, Hoover R, Brown K, Kooperberg C, Risch HA, Jacobs EJ, Li D, Yu K, Shu XO, Chanock SJ, Wolpin BM, Stolzenberg-Solomon RZ, Chatterjee N, Klein AP, Smith JP, Kraft P, Shi J, Petersen GM, Zheng W, Amundadottir LT. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. J Natl Cancer Inst 2020;112:1003-12. [PMID: 31917448 DOI: 10.1093/jnci/djz246] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
54 Petersen GM. Familial pancreatic cancer. Semin Oncol 2016;43:548-53. [PMID: 27899186 DOI: 10.1053/j.seminoncol.2016.09.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
55 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book 2017. [DOI: 10.1200/edbk_175222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Hoskins JW, Ibrahim A, Emmanuel MA, Manmiller SM, Wu Y, O'Neill M, Jia J, Collins I, Zhang M, Thomas JV, Rost LM, Das S, Parikh H, Haake JM, Matters GL, Kurtz RC, Bamlet WR, Klein A, Stolzenberg-Solomon R, Wolpin BM, Yarden R, Wang Z, Smith J, Olson SH, Andresson T, Petersen GM, Amundadottir LT. Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. Hum Mol Genet 2016;25:4726-38. [PMID: 28172817 DOI: 10.1093/hmg/ddw300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
57 Jermusyk A, Zhong J, Connelly KE, Gordon N, Perera S, Abdolalizadeh E, Zhang T, O'Brien A, Hoskins JW, Collins I, Eiser D, Yuan C, Risch HA, Jacobs EJ, Li D, Du M, Stolzenberg-Solomon RZ, Klein AP, Smith JP, Wolpin BM, Chanock SJ, Shi J, Petersen GM, Westlake CJ, Amundadottir LT; PanScan Consortium., PanC4 Consortium. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Am J Hum Genet 2021;108:1852-65. [PMID: 34559995 DOI: 10.1016/j.ajhg.2021.09.002] [Reference Citation Analysis]